Peter Horby, Professor of Emerging Infectious Diseases and Global Health in the Nuffield Department of Medicine, University of Oxford, and Joint Chief Investigator for the trial, says, ‘The RECOVERY trial has been an enormous success, enrolling over 37,000 patients and delivering clear results on six treatments already. By building on this success through international partnership we can speed up the assessment of novel treatments, increase the global relevance of the trial results, build capacity, and reduce wasted efforts on small uninformative studies.’
‘It is particularly important to find readily available and affordable treatments for COVID-19 that can be used worldwide. RECOVERY International will help us to identify effective treatments that can be used in less well-resourced settings’ he added.
The RECOVERY trial was launched rapidly in the UK in March 2020 to investigate if any existing treatments were effective against COVID-19. It is open to all patients admitted to NHS hospitals with COVID-19, with more than 36,000 patients recruited so far. The trial has already delivered results that have changed clinical care, including the findings that the inexpensive steroid, dexamethasone, and the anti-inflammatory treatment, tocilizumab, significantly reduce the risk of death when given to hospitalised patients with severe COVID-19.
The expansion of RECOVERY internationally has been made possible thanks to the longstanding work of the Oxford University Clinical Research Unit (OUCRU), which has campuses in Kathmandu in Nepal (OUCRU Nepal) and Jakarta in Indonesia (Eijkman-Oxford Clinical Research Unit, EOCRU).In Indonesia and Nepal, the trial will initially focus on the treatments aspirin and colchicine, since these are readily available and affordable but, like RECOVERY in the UK, the trial is adaptive and new drugs will be added over time.
OUCRU Nepal exists in partnership with Patan Academy of Health Sciences and Patan Hospital in Kathmandu and the trial is being delivered in collaboration with the Nepal Health Research Council. In Indonesia, the RECOVERY trial is being delivered through the longstanding research partnership between the University of Oxford and Faculty of Medicine University of Indonesia (FKUI), and several hospitals.
Funding for RECOVERY International was provided by Wellcome, in collaboration with the UK Foreign, Commonwealth and Development Office (FCDO), on behalf of the COVID-19 Therapeutics Accelerator, initially for a two-year period.
Dr Erni Nelwan, who will lead the trial in Indonesia on behalf of FKUI, says, ‘We are really excited that our investigators will have the experience of being part of a high-profile, global trial. In return, we can provide a more diverse patient population, including those more severely affected by the disease.’
‘RECOVERY has already helped Indonesia to plan its resources more effectively. For instance, because of the trial’s results, chloroquine/hydroxychloroquine is no longer recommended in Indonesia to treat COVID-19, with dexamethasone now widely used instead,’ says Professor Raph Hamers, who will co-lead the trial in Indonesia on behalf of Oxford University.
‘The Nepal team is super-excited to be aligned with Oxford University’s RECOVERY, the largest COVID-19 drug trial in the world so that these ground-breaking findings also become relevant in the context of low- and middle-income countries,’ adds Professor Buddha Basnyat, Director of OUCRU Nepal.
The Co-lead from Nepal, Dr Pradip Gyanwali, member secretary of the Nepal Health Research Council adds that Recovery International has excellent potential for being very useful for Nepal.
‘Launching RECOVERY internationally is a tremendous achievement,’ says Emmanuelle Denis, who liaises between the main Oxford-based RECOVERY team and the overseas sites. ‘In the UK, the trial could be rolled out rapidly thanks to the joined-up nature of the NHS. It is much more challenging to replicate such a large trial in countries without this integrated infrastructure, but thanks to our longstanding relationships and the willingness of research partners in Nepal and Indonesia to be involved, we are now able to recruit in these countries.’
Dr Nick Cammack, COVID-19 Therapeutics Lead at Wellcome, says, ‘The opening of an international RECOVERY trial is an important moment in the search for effective treatments against COVID-19 that can be used across the globe. Researching treatments that are affordable and readily accessible in low- and middle-income countries means that the results can be rapidly utilised in these nations.
‘This new research will also help us to understand how other diseases that are endemic in some countries, such as TB and HIV, can affect COVID-19 and its treatments.
‘COVID-19 can be a preventable and treatable disease, but only if we invest in research now. A pipeline of new treatments is essential if we are to reduce further deaths and suffering, and to keep pressure off health systems. Investing in research into a wide range of treatments, alongside vaccines and testing, and ensuring all advances are fairly available globally, remains our only exit from the pandemic.’
Funders
Funding for RECOVERY International is provided by the Wellcome Trust Grant Ref: 222406/Z/20/Z through the COVID-19 Therapeutics Accelerator.
The RECOVERY trial is conducted by the registered clinical trials units with the Nuffield Department of Population Health in partnership with the Nuffield Department of Medicine. The trial is supported by a grant to the University of Oxford from UK Research and Innovation/National Institute for Health Research (NIHR) and by core funding provided by NIHR Oxford Biomedical Research Centre, Wellcome, the Bill and Melinda Gates Foundation, the Foreign, Commonwealth & Development Office, Health Data Research UK, the Medical Research Council Population Health Research Unit, and NIHR Clinical Trials Unit Support Funding.
